Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.

Ricke J, Klümpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, Gasbarrini A, Pech M, Peck-Radosavljevic M, Popovič P, Rosmorduc O, Schott E, Seidensticker M, Verslype C, Sangro B, Malfertheiner P.

J Hepatol. 2019 Aug 14. pii: S0168-8278(19)30472-6. doi: 10.1016/j.jhep.2019.08.006. [Epub ahead of print]

PMID:
31421157
2.

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).

Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM.

Oncoimmunology. 2019 Jun 3;8(8):1615817. doi: 10.1080/2162402X.2019.1615817. eCollection 2019.

3.

Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography.

Gougelet A, Sartor C, Senni N, Calderaro J, Fartoux L, Lequoy M, Wendum D, Talbot JN, Prignon A, Chalaye J, Imbeaud S, Zucman-Rossi J, Tordjmann T, Godard C, Bossard P, Rosmorduc O, Amaddeo G, Colnot S.

Gastroenterology. 2019 Sep;157(3):807-822. doi: 10.1053/j.gastro.2019.05.069. Epub 2019 Jun 10.

PMID:
31194980
4.

Insulin receptor isoform A favors tumor progression in human hepatocellular carcinoma by increasing stem/progenitor cell features.

Benabou E, Salamé Z, Wendum D, Lequoy M, Tahraoui S, Merabtene F, Chrétien Y, Scatton O, Rosmorduc O, Fouassier L, Fartoux L, Praz F, Desbois-Mouthon C.

Cancer Lett. 2019 May 28;450:155-168. doi: 10.1016/j.canlet.2019.02.037. Epub 2019 Mar 6.

5.

LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.

Poynard T, Peta V, Deckmyn O, Munteanu M, Moussalli J, Ngo Y, Rudler M, Lebray P, Pais R, Bonyhay L, Charlotte F, Thibault V, Fartoux L, Lucidarme O, Eyraud D, Scatton O, Savier E, Valantin MA, Ngo A, Drane F, Rosmorduc O, Imbert-Bismut F, Housset C, Thabut D, Ratziu V; HECAM-FibroFrance Group.

Aliment Pharmacol Ther. 2019 Feb;49(3):308-320. doi: 10.1111/apt.15082. Epub 2018 Dec 19.

6.

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.

Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J.

J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.

PMID:
29704513
7.

[Treatment of the advanced HCC: A second revolution by using immunotherapy].

Fartoux L, Rosmorduc O.

Biol Aujourdhui. 2018;212(3-4):85-87. doi: 10.1051/jbio/2018027. Epub 2019 Apr 11. Review. French.

PMID:
30973137
8.

Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.

Pais R, Fartoux L, Goumard C, Scatton O, Wendum D, Rosmorduc O, Ratziu V.

Aliment Pharmacol Ther. 2017 Nov;46(9):856-863. doi: 10.1111/apt.14261. Epub 2017 Aug 31.

9.

Growth factor receptor binding protein 14 inhibition triggers insulin-induced mouse hepatocyte proliferation and is associated with hepatocellular carcinoma.

Morzyglod L, Caüzac M, Popineau L, Denechaud PD, Fajas L, Ragazzon B, Fauveau V, Planchais J, Vasseur-Cognet M, Fartoux L, Scatton O, Rosmorduc O, Guilmeau S, Postic C, Desdouets C, Desbois-Mouthon C, Burnol AF.

Hepatology. 2017 Apr;65(4):1352-1368. doi: 10.1002/hep.28972. Epub 2017 Feb 21.

PMID:
27981611
10.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators.

Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Erratum in: Lancet. 2017 Jan 7;389(10064):36.

PMID:
27932229
11.

Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.

Buta C, Benabou E, Lequoy M, Régnault H, Wendum D, Merabtene F, Chettouh H, Aoudjehane L, Conti F, Chrétien Y, Scatton O, Rosmorduc O, Praz F, Fartoux L, Desbois-Mouthon C.

J Exp Clin Cancer Res. 2016 Sep 28;35(1):154. No abstract available.

12.

Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.

Buta C, Benabou E, Lequoy M, Régnault H, Wendum D, Meratbene F, Chettouh H, Aoudjehane L, Conti F, Chrétien Y, Scatton O, Rosmorduc O, Praz F, Fartoux L, Desbois-Mouthon C.

J Exp Clin Cancer Res. 2016 Aug 11;35(1):126. doi: 10.1186/s13046-016-0402-3. Erratum in: J Exp Clin Cancer Res. 2016;35(1):154.

13.

Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis.

Lequoy M, Desbois-Mouthon C, Wendum D, Gupta V, Blachon JL, Scatton O, Dumont S, Bonnemaire M, Schmidlin F, Rosmorduc O, Fartoux L.

Histopathology. 2017 Feb;70(3):492-498. doi: 10.1111/his.13034. Epub 2016 Nov 10.

PMID:
27391928
14.

Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.

Zhu AX, Kang YK, Rosmorduc O, Evans TR, Santoro A, Ross P, Gane E, Vogel A, Jeffers M, Meinhardt G, Peña CE.

Clin Cancer Res. 2016 Oct 1;22(19):4870-4879. Epub 2016 May 24.

15.

Liver biopsy for diagnosis of presumed benign hepatocellular lesions lacking magnetic resonance imaging diagnostic features of focal nodular hyperplasia.

Sannier A, Cazejust J, Lequoy M, Cervera P, Scatton O, Rosmorduc O, Wendum D.

Liver Int. 2016 Nov;36(11):1668-1676. doi: 10.1111/liv.13113. Epub 2016 Mar 30.

PMID:
26969817
16.

Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group.

Spano JP, Poizot-Martin I, Costagliola D, Boué F, Rosmorduc O, Lavolé A, Choquet S, Heudel PE, Leblond V, Gabarre J, Valantin MA, Solas C, Guihot A, Carcelain G, Autran B, Katlama C, Quéro L.

Ann Oncol. 2016 Mar;27(3):397-408. doi: 10.1093/annonc/mdv606. Epub 2015 Dec 17. Review.

PMID:
26681686
17.

Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation.

Scatton O, Goumard C, Cauchy F, Fartoux L, Perdigao F, Conti F, Calmus Y, Boelle PY, Belghiti J, Rosmorduc O, Soubrane O.

J Surg Oncol. 2015 Jun;111(8):1007-15. doi: 10.1002/jso.23916. Epub 2015 Apr 28.

PMID:
25918872
18.

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK.

J Clin Oncol. 2015 Feb 20;33(6):559-66. doi: 10.1200/JCO.2013.53.7746. Epub 2014 Dec 29.

19.

Evidence-based integration of selective internal radiation therapy into the management of cholangiocarcinoma.

Fartoux L, Rosmorduc O.

Future Oncol. 2014 Nov;10(15 Suppl):89-92. doi: 10.2217/fon.14.232. Review. No abstract available.

PMID:
25478776
20.

[Metabolic syndrome, non alcoholic hepatic steatopathy and hepatocellular carcinoma: so dangerous liaisons].

Rosmorduc O, Fartoux L.

Bull Acad Natl Med. 2014 Dec;198(9):1653-63; discussion 1663-4. French.

PMID:
27356367
21.

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF; BINGO investigators.

Lancet Oncol. 2014 Jul;15(8):819-28. doi: 10.1016/S1470-2045(14)70212-8. Epub 2014 May 19.

22.

18F-fluorocholine may be taken-up by brown adipose tissue.

Balogova S, Michaud L, Vereb M, Decazes P, Huchet V, Kerrou K, Fartoux L, Montravers F, Rosmorduc O, Talbot JN.

Nuklearmedizin. 2013;52(1):N3-4. No abstract available.

PMID:
24395333
23.

Prevalence of low phospholipid-associated cholelithiasis in young female patients.

Condat B, Zanditenas D, Barbu V, Hauuy MP, Parfait B, El Naggar A, Collot V, Bonnet J, Ngo Y, Maftouh A, Dugué L, Balian C, Charlier A, Blazquez M, Rosmorduc O.

Dig Liver Dis. 2013 Nov;45(11):915-9. doi: 10.1016/j.dld.2013.04.002. Epub 2013 May 16.

PMID:
23684896
24.

Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.

Chettouh H, Fartoux L, Aoudjehane L, Wendum D, Clapéron A, Chrétien Y, Rey C, Scatton O, Soubrane O, Conti F, Praz F, Housset C, Rosmorduc O, Desbois-Mouthon C.

Cancer Res. 2013 Jul 1;73(13):3974-86. doi: 10.1158/0008-5472.CAN-12-3824. Epub 2013 Apr 30.

25.

Relationship between hepatocellular carcinoma, metabolic syndrome and non-alcoholic fatty liver disease: which clinical arguments?

Rosmorduc O.

Ann Endocrinol (Paris). 2013 May;74(2):115-20. doi: 10.1016/j.ando.2013.02.008. Epub 2013 Apr 15. Review.

PMID:
23597944
26.

Hepatobiliary anomalies associated with ABCB4/MDR3 deficiency in adults: a pictorial essay.

Benzimra J, Derhy S, Rosmorduc O, Menu Y, Poupon R, Arrivé L.

Insights Imaging. 2013 Jun;4(3):331-8. doi: 10.1007/s13244-013-0243-y. Epub 2013 Apr 17.

27.

Genotype-phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: a study of 156 consecutive patients.

Poupon R, Rosmorduc O, Boëlle PY, Chrétien Y, Corpechot C, Chazouillères O, Housset C, Barbu V.

Hepatology. 2013 Sep;58(3):1105-10. doi: 10.1002/hep.26424. Epub 2013 Jul 29.

PMID:
23533021
28.

Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Verslype C, Rosmorduc O, Rougier P; ESMO Guidelines Working Group.

Ann Oncol. 2012 Oct;23 Suppl 7:vii41-8. No abstract available.

PMID:
22997453
29.

Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.

Zaanan A, Williet N, Hebbar M, Dabakuyo TS, Fartoux L, Mansourbakht T, Dubreuil O, Rosmorduc O, Cattan S, Bonnetain F, Boige V, Taïeb J.

J Hepatol. 2013 Jan;58(1):81-8. doi: 10.1016/j.jhep.2012.09.006. Epub 2012 Sep 16.

PMID:
22989572
30.

A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection.

Fartoux L, Balogova S, Nataf V, Kerrou K, Huchet V, Rosmorduc O, Talbot JN.

Nucl Med Commun. 2012 Jul;33(7):757-65. doi: 10.1097/MNM.0b013e328350fb9f.

PMID:
22504293
31.

Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.

Blivet-Van Eggelpoël MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, Rey C, Priam S, Housset C, Rosmorduc O, Desbois-Mouthon C.

J Hepatol. 2012 Jul;57(1):108-15. doi: 10.1016/j.jhep.2012.02.019. Epub 2012 Mar 10.

PMID:
22414764
32.

Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations.

Wendum D, Barbu V, Rosmorduc O, Arrivé L, Fléjou JF, Poupon R.

Virchows Arch. 2012 Mar;460(3):291-8. doi: 10.1007/s00428-012-1202-6. Epub 2012 Feb 14.

PMID:
22331132
33.

HCC and NASH: how strong is the clinical demonstration?

Rosmorduc O, Fartoux L.

Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):202-8. doi: 10.1016/j.clinre.2011.12.011. Epub 2012 Feb 10. Review.

PMID:
22326764
34.

Targeting STAT3 in hepatocellular carcinoma: sorafenib again….

Rosmorduc O, Desbois-Mouthon C.

J Hepatol. 2011 Nov;55(5):957-9. doi: 10.1016/j.jhep.2011.06.005. Epub 2011 Jun 28. No abstract available.

35.

[Hepatocellular adenoma. Answer to December e-quid].

Jauregui G, El Mouhadi S, Rosmorduc O, Wendum D, Menu Y, Arrivé L.

J Radiol. 2011 Jan;92(1):82-5. doi: 10.1016/j.jradio.2010.11.005. Epub 2011 Feb 15. French. No abstract available.

PMID:
21352735
36.

Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease.

Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, Huchet V, Ancel D, Grange JD, Rosmorduc O.

J Nucl Med. 2010 Nov;51(11):1699-706. doi: 10.2967/jnumed.110.075507. Epub 2010 Oct 18.

37.

The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study.

Lewin M, Fartoux L, Vignaud A, Arrivé L, Menu Y, Rosmorduc O.

Eur Radiol. 2011 Feb;21(2):281-90. doi: 10.1007/s00330-010-1914-4. Epub 2010 Aug 5.

PMID:
20683597
38.

Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease.

Rosmorduc O, Housset C.

Semin Liver Dis. 2010 Aug;30(3):258-70. doi: 10.1055/s-0030-1255355. Epub 2010 Jul 21. Review.

PMID:
20665378
39.

Antiangiogenic therapies in portal hypertension: a breakthrough in hepatology.

Rosmorduc O.

Gastroenterol Clin Biol. 2010 Sep;34(8-9):446-9. doi: 10.1016/j.gcb.2010.05.007. Epub 2010 Jul 13. Review.

40.

The cholangiographic features of severe forms of ABCB4/MDR3 deficiency-associated cholangiopathy in adults.

Poupon R, Arrive L, Rosmorduc O.

Gastroenterol Clin Biol. 2010 Aug-Sep;34(6-7):380-7. doi: 10.1016/j.gcb.2010.04.011. Epub 2010 May 27.

41.

[Use of sorafenib in patients with hepatocellular or renal carcinoma].

Rosmorduc O, Chevreau C, Dielenseger P, Ederhy S, Goldwasser F, Grange JD, Mortier L, Neidhardt-Berard ME, Robert C, Scotté F, Seitz JF.

Gastroenterol Clin Biol. 2010 Mar;34(3):161-7. doi: 10.1016/j.gcb.2009.12.004. Epub 2010 Feb 23. Review. French.

42.

Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.

Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A, Bolondi L.

Eur J Gastroenterol Hepatol. 2010 Apr;22(4):391-8. doi: 10.1097/MEG.0b013e328333df23.

PMID:
19940784
43.

Combined features of low phospholipid-associated cholelithiasis and progressive familial intrahepatic cholestasis 3.

Poupon R, Barbu V, Chamouard P, Wendum D, Rosmorduc O, Housset C.

Liver Int. 2010 Feb;30(2):327-31. doi: 10.1111/j.1478-3231.2009.02148.x. Epub 2009 Oct 19.

PMID:
19840255
44.

Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.

Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O.

Clin Cancer Res. 2009 Sep 1;15(17):5445-56. doi: 10.1158/1078-0432.CCR-08-2980. Epub 2009 Aug 25.

45.

[Hepatocellular carcinoma management in the era of sorafenib].

Rosmorduc O.

Gastroenterol Clin Biol. 2009 Apr;33(4):327-33. doi: 10.1016/j.gcb.2009.02.010. Epub 2009 Mar 24. French. No abstract available.

46.

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.

André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W.

Br J Cancer. 2008 Sep 16;99(6):862-7. doi: 10.1038/sj.bjc.6604628.

47.

[Management of hepatocellular carcinoma. Where are we now? What's next?].

Taieb J, Barbare JC, Boussaha T, Cunha AS, Baere Td, Rosmorduc O, Zucman-Rossi J, Franco D.

Bull Cancer. 2009 Jan;96(1):19-34. doi: 10.1684/bdc.2009.0790. Review. French.

48.

[Therapeutic advances in hepatocellular carcinoma].

Poupon R, Fartoux L, Rosmorduc O.

Bull Acad Natl Med. 2008 Jan;192(1):23-31; discussion 31-2. Review. French.

PMID:
18663979
49.

ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults.

Ziol M, Barbu V, Rosmorduc O, Frassati-Biaggi A, Barget N, Hermelin B, Scheffer GL, Bennouna S, Trinchet JC, Beaugrand M, Ganne-Carrié N.

Gastroenterology. 2008 Jul;135(1):131-41. doi: 10.1053/j.gastro.2008.03.044. Epub 2008 Mar 26. Erratum in: Gastroenterology. 2008 Oct;135(4):1429.

PMID:
18482588
50.

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.

Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi S S, Mansoubakht T, Artru P, Poynard T, Rosmorduc O, Hebbar M, Taieb J.

Cancer. 2008 Jun 15;112(12):2733-9. doi: 10.1002/cncr.23489.

Supplemental Content

Loading ...
Support Center